Key findings of study – Patients who received Rituximab with chemo followed by maintenance therapy had an improved 5-year progression free survival and overall survival independent of prognostic factors. A reduction of the risk of transformation was observed among the maintenance patients of the training, but not of the validation, cohort.
Home / Resource Library / Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study